Stroke Management Market Outlook 2022, Industry Growth, Top Manufactures, Key Segments, Current Trends and Future Prospect to 2028

The stroke management market is expected to grow from US$ 33.48 billion in 2021 to US$ 55.37 billion by 2028; it is expected to grow at a CAGR of 7.5% from 2022 to 2028.

The increasing incidence of chronic diseases, including hypertension, hyperlipidemia, and diabetes, has contributed to the growth of the stroke management market. Hypertension is the leading risk factor for stroke as blood pressure higher than 140/90mmHg can damage the blood vessels that supply blood to the brain. Furthermore, diabetes is also a major cause of stroke. As per the American Stroke Association, people with diabetes have twice the chance of having a stroke, and may also witness the early onset of stroke. Further, within every two minutes, an adult with diabetes is hospitalized due to stroke in US, as per the same data.

Click to Get PDF Sample of this Report at https://www.theinsightpartners.com/sample/TIPRE00003527/?utm_source=OpenPR&utm_medium=10396

As a result, the market leaders are working to develop innovative treatments for stroke, and a wide variety of new drugs and devices are under investigation for treatment and diagnosis of all major types of strokes, and many of them are expected to receive approval in the near future. For instance, in September 2020, Johnson & Johnson announced the launch of Cerenovus Stroke Solutions, which consists of three devices that can assist physicians in removing clots. Furthermore, in August 2021, MicroTransponder Inc. received FDA approval for Vivistim System, a first-of-its-kind stroke rehabilitation system, for the treatment of moderate to severe upper extremity motor deficits associated with chronic ischemic stroke.

Some of the companies competing in the Stroke Management Market are-
• Abbott Laboratories
• B Braun Melsungen AG
• Boston Scientific Corporation
• Bristol Myers Squibb Co.
• Cardinal Health Inc.
• General Electric Company
• Glaxosmithkline Plc
• Medtronic Plc
• Merck And Co. Inc.
• Siemens AG.

Hypertension is the leading risk factor for stroke as blood pressure higher than 140/90mmHg can damage the blood vessels that supply blood to the brain. Furthermore, diabetes is also a major cause of stroke. As per the American Stroke Association, people with diabetes have twice the chance of having a stroke and may also witness the early onset of stroke. Further, within every two minutes, an adult with diabetes is hospitalized due to stroke in US, as per the same data. As a result, the demand for stroke medications is increasing continuously, and it is expected to grow tremendously in the coming years.

The healthcare expenditure has created ample opportunities for developing nations to provide better services and facilities to their people. Adoption of available treatments, including the application of tissue plasmogen activators, anticoagulants, antiplatelet drugs, and antihypertensives, is likely to rise in emerging regions such as Asia-Pacific and Middle East & Africa. These regions are investing a significant amount in their healthcare sectors, and the awareness regarding health has notably increased. Additionally, the increasing incidences of other stroke-associated risk factors such as atherosclerosis, arrhythmia, cardiac structural abnormalities, and obesity are offering potential opportunities for the stroke management market.

Segments of the Report:

Based on application, the stroke management market is bifurcated into ischemic stroke and haemorrhagic stroke. The ischemic stroke segment accounted for a larger market share in 2021, and it is expected to dominate the market over the forecast period. Various drugs such as Ticagrelor, Alteplase, and Clopidogrel, are currently available for the management of ischemic stroke, while few of the candidates are under investigation for treatment and diagnosis of ischemic stroke, and many new devices and drugs are expected to receive approval in the near future. Further, drugs such as neuropeptides are also emerging as novel treatments for stroke, and virtual reality (VR) based therapies are also demonstrating positive effects in the treatment of chronic stroke in clinical trials.

Get a Lucrative Discount at https://www.theinsightpartners.com/discount/TIPRE00003527/?utm_source=OpenPR&utm_medium=10396

Reasons for buy this Report
• Highlights key business priorities to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the Stroke Management market, thereby allowing players to develop effective long term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest to components, type, and end-users.

Other Healthcare Reports-

https://www.marketwatch.com/press-release/cardiovascular-devices-market-competitive-analysis-2022-with-business-scope-opportunities-in-grooming-regions-latest-trends-and-global-industry-size-analysis-till-2028-research-with-covid-19-impact-2022-10-12?mod=search_headline

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.